| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MBA, as Chief Financial Officer.
"I am delighted to welcome Matthew to our team," said Andrew Oxtoby, President and Chief Executive Officer of Kalaris Therapeutics. "Matt is an experienced chief financial officer and strategic leader with a track record of successfully scaling up biopharmaceutical companies, directing capital raising rounds, and negotiating highly beneficial partnership deals. He will be a valuable addition to our leadership team and will support our company's evolution as we advance our clinical development efforts."
Matthew Gall said, "I am excited to join Kalaris Therapeutics' leadership team at this critical time in the company's trajectory. I look forward to helping Kalaris achieve its mission to change the treatment landscape for those living with retinal diseases."
Mr. Gall most recently served as Chief Financial Officer of iTeos Therapeutics, where he was responsible for business development and overall financial operations and strategy. Prior to iTeos, Mr. Gall held positions of increasing responsibility at Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences across the finance and business development functions. Mr. Gall earned a Bachelor of Science in Business Administration from Bowling Green State University and a Master of Business Administration from The University of Chicago.
Posted In: KLRS
